ChemoCentryx (NASDAQ:CCXI) was upgraded by research analysts at BidaskClub from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Wednesday.
Separately, JPMorgan Chase & Co. reaffirmed an “overweight” rating and set a $16.00 target price (up from $13.00) on shares of ChemoCentryx in a research note on Tuesday. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and one has given a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $12.13.
Shares of ChemoCentryx (NASDAQ CCXI) traded up $0.53 during mid-day trading on Wednesday, hitting $13.32. 381,673 shares of the stock traded hands, compared to its average volume of 302,700. The company has a market cap of $596.34, a P/E ratio of 37.19 and a beta of 1.89. ChemoCentryx has a 12-month low of $5.42 and a 12-month high of $13.84.
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Wells Fargo & Company MN grew its stake in ChemoCentryx by 3.2% during the second quarter. Wells Fargo & Company MN now owns 23,595 shares of the biopharmaceutical company’s stock valued at $221,000 after acquiring an additional 729 shares in the last quarter. Teachers Advisors LLC grew its stake in ChemoCentryx by 3.9% during the second quarter. Teachers Advisors LLC now owns 41,878 shares of the biopharmaceutical company’s stock valued at $392,000 after acquiring an additional 1,590 shares in the last quarter. The Manufacturers Life Insurance Company grew its stake in ChemoCentryx by 14.5% during the second quarter. The Manufacturers Life Insurance Company now owns 22,514 shares of the biopharmaceutical company’s stock valued at $211,000 after acquiring an additional 2,852 shares in the last quarter. Voya Investment Management LLC grew its stake in ChemoCentryx by 22.8% during the second quarter. Voya Investment Management LLC now owns 15,984 shares of the biopharmaceutical company’s stock valued at $150,000 after acquiring an additional 2,965 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership grew its stake in ChemoCentryx by 44.5% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 26,016 shares of the biopharmaceutical company’s stock valued at $155,000 after acquiring an additional 8,017 shares in the last quarter. 48.55% of the stock is owned by institutional investors.
TRADEMARK VIOLATION NOTICE: This story was first published by Markets Daily and is the sole property of of Markets Daily. If you are viewing this story on another site, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark laws. The original version of this story can be read at https://www.themarketsdaily.com/2018/03/14/chemocentryx-ccxi-raised-to-hold-at-bidaskclub.html.
ChemoCentryx, Inc is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact.
Receive News & Ratings for ChemoCentryx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx and related companies with MarketBeat.com's FREE daily email newsletter.